ESC TV 2014 - ISCHEMIA AND CORONARY ARTERY DISEASE
ESC TV 2014 - ISCHEMIA AND CORONARY ARTERY DISEASE
- ODYSSEY - Alirocumab evaluation in the ODYSSEY Combo II, HF I and II and ODYSSEY Long term
Christopher CANNON - Boston, US
- SIGNIFY - Ivabradine in patients with stable coronary artery disease without clinical heart failure
Kim FOX - London, GB
- Pharmacology - Important drug interactions, what you should know ?
Christian FUNCK-BRENTANO - Paris, FR
Content
17.6 -> ali rakumab is a new lipid-lowering
19.92 -> agent
20.4 -> a fully human monoclonal antibody
22.64 -> administered every two weeks by
24.64 -> subcutaneous injection for which three
27.279 -> trials in the odyssey series
29.119 -> combo 2 fh 1 and 2 and odyssey long term
33.36 -> were reported at an esc 2014 hotline
36.48 -> session
37.04 -> well we've seen across the different
38.8 -> studies that this treatment of the sub-q
41.44 -> injection given for a year works it's
44.559 -> well tolerated
45.76 -> and produces 50 to 60 percent depending
49.36 -> on the dosing
50.239 -> reductions in ldl cholesterol it gives
52.719 -> us great encouragement
54.48 -> that these dramatic reductions in ldl
58.239 -> will translate into reductions in
60.96 -> cardiovascular events
71.04 -> signify is a large randomized study
74.32 -> designed to evaluate the impact of heart
76.64 -> rate reduction
77.84 -> by evaporadine in patients with stable
80.24 -> coronary artery disease
81.68 -> without clinical heart failure we found
84.799 -> that
85.119 -> reducing the heart rate with evaporating
87.84 -> using a high dose of
89.2 -> abradine and effectively reducing the
91.04 -> heart rate we had no effect
92.96 -> in terms of cardiovascular death and
95.439 -> non-fatal myocardial infarction
97.28 -> we had specifically expected to find a
100.479 -> beneficial result
101.84 -> in the patients with angina and to our
103.92 -> surprise what we found
105.759 -> was an increased incidence of the
107.759 -> primary endpoint that's cardiovascular
109.52 -> death
110.24 -> non-fatal myocardial infarction in the
112.32 -> patients with angina
113.759 -> there's one definite conclusion and that
116.079 -> is
116.88 -> that lowering heart rate in patients
119.52 -> with coronary artery disease
121.119 -> and without heart failure does not
123.92 -> improve outcome
125.119 -> does not prevent the progression of
126.88 -> coronary artery disease
128.56 -> you cannot do that by lowering heart
130.72 -> rate
139.12 -> many drug interactions exist most of
141.599 -> them
142.239 -> are not important to consider and may
144.959 -> actually have good
146.64 -> effects good therapeutic effect main
149.36 -> message is
150.879 -> be able to identify the rare patients
154.319 -> who will have
155.2 -> major adverse drug reactions due to drug
158.64 -> drug interactions
160.4 -> because these these patients may die
162.56 -> from drug drug interactions
164.48 -> elderly patients polypharmacy
167.84 -> the kidney is a very important target
170.16 -> and bleeding complications
172.16 -> and final message don't rely on your
174.8 -> memory
175.599 -> and access websites to look at the drug
178.319 -> attractions
179.36 -> with the patient in front of you
189.36 -> you
Source: https://www.youtube.com/watch?v=B8lhYtLKVwE